Live Feeds
● LIVE Updated 1h ago · 8 sources tracked

Johnson & Johnson buys eye disease biotech for up to $3.3bn

Johnson & Johnson agreed to buy Austin-based Ollin Biosciences for $2.2 billion upfront plus milestone payments that could raise the total value to $3.3 billion. The deal adds a Phase III bispecific antibody candidate targeting wet age-related macular degeneration and diabetic macular edema, positioning J&J to compete with Roche's Vabysmo in the ophthalmology market.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (8)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Johnson & Johnson will pay $2.2 billion upfront to acquire Ollin Biosciences.
  • ✓ The total deal value could reach $3.3 billion including milestone payments.
  • ✓ Ollin Biosciences is based in Austin, Texas.
  • ✓ Ollin's lead asset is a bispecific antibody in Phase III development for wet age-related macular degeneration and diabetic macular edema.
🛡️ Source Corroboration: 8 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

J&J announced a definitive agreement to acquire Ollin Biosciences for $2.2bn upfront and up to $3.3bn total, adding a Phase III bispecific antibody for wAMD and DME.

Live updates

  1. Johnson & Johnson acquires Ollin Biosciences for up to $3.3bn

    Johnson & Johnson agreed to buy Austin-based Ollin Biosciences for $2.2 billion upfront plus milestone payments that could raise the total value to $3.3 billion. The deal adds a Phase III bispecific antibody candidate targeting wet age-related macular degeneration and diabetic macular edema, positioning J&J to compete with Roche's Vabysmo in the ophthalmology market.

    Why it matters

    The acquisition bolsters J&J's ophthalmology pipeline with a late-stage asset that could challenge the current standard of care. Ollin's bispecific antibody is designed to inhibit two pathways involved in retinal vascular leakage and abnormal blood vessel growth. The transaction reflects continued consolidation in eye-disease therapeutics as large pharma seeks to replace or supplement anti-VEGF franchises.

    What is confirmed

    • Johnson & Johnson will pay $2.2 billion upfront to acquire Ollin Biosciences.
    • The total deal value could reach $3.3 billion including milestone payments.
    • Ollin Biosciences is based in Austin, Texas.
    • Ollin's lead asset is a bispecific antibody in Phase III development for wet age-related macular degeneration and diabetic macular edema.
    • The therapy is intended to compete with Roche's Vabysmo.

    Still unconfirmed

    • One source cited a potential total value of $3.4 billion rather than $3.3 billion.

    What to watch next

    • Regulatory clearance of the acquisition
    • Phase III trial readouts for Ollin's bispecific antibody
    • Commercial launch timeline if trials succeed
    Sources used for this update (8)
    1. Financial Times — Johnson & Johnson buys eye disease biotech for up to $3.3bn
    2. Yahoo Finance — J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says
    3. Fierce Biotech — J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
    4. WSJ — Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion
    5. The Business Journals — Austin biotech startup to be acquired by Johnson & Johnson for $3.3B
    6. CNBC — J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion
    7. www.financierworldwide.com — Johnson & Johnson agree Ollin Biosciences deal
    8. www.pharmaceutical-technology.com — J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community